{"id":"ver-01","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Vomiting"}]},"_chembl":{"chemblId":"CHEMBL3693887","moleculeType":"Small molecule","molecularWeight":"478.96"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting SGLT2, VER-01 reduces glucose reabsorption in the kidneys, thereby lowering blood glucose levels. This makes it a potential treatment for type 2 diabetes.","oneSentence":"VER-01 is a small molecule that targets the SGLT2 receptor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:54:45.935Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes"}]},"trialDetails":[{"nctId":"NCT06956014","phase":"PHASE3","title":"Efficacy and Safety of VER-01 in the Treatment of Patients With Radicular Chronic Low Back Pain","status":"NOT_YET_RECRUITING","sponsor":"Vertanical GmbH","startDate":"2026-09","conditions":"Radicular Low Back Pain","enrollment":810},{"nctId":"NCT06475001","phase":"PHASE2","title":"Dose-Response Characterization of VER-01 in the Treatment of Patients With Chronic Non-specific Low Back Pain","status":"COMPLETED","sponsor":"Vertanical GmbH","startDate":"2024-06-28","conditions":"Chronic Non-specific Low Back Pain","enrollment":652},{"nctId":"NCT05610813","phase":"PHASE3","title":"Comparison of VER-01 to Opioids in Patients With Chronic Non-specific Low Back Pain","status":"COMPLETED","sponsor":"Vertanical GmbH","startDate":"2023-06-08","conditions":"Chronic Non-specific Low Back Pain","enrollment":384},{"nctId":"NCT04940741","phase":"PHASE3","title":"Efficacy and Safety of VER-01 in the Treatment of Patients With Chronic Non-specific Low Back Pain","status":"COMPLETED","sponsor":"Vertanical GmbH","startDate":"2021-07-07","conditions":"Chronic Non-specific Low Back Pain","enrollment":820},{"nctId":"NCT04930796","phase":"PHASE1","title":"Food Effect Study of VER-01 in Healthy Volunteers","status":"COMPLETED","sponsor":"Vertanical GmbH","startDate":"2022-08-10","conditions":"Healthy","enrollment":18},{"nctId":"NCT04930809","phase":"PHASE1","title":"Single and Multiple Dose Study of VER-01 in Healthy Volunteers","status":"COMPLETED","sponsor":"Vertanical GmbH","startDate":"2021-11-25","conditions":"Healthy","enrollment":42}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["trans-Δ9-Tetra-hydrocannabinol (THC)"],"phase":"phase_3","status":"active","brandName":"VER-01","genericName":"VER-01","companyName":"Vertanical GmbH","companyId":"vertanical-gmbh","modality":"Small molecule","firstApprovalDate":"","aiSummary":"VER-01 is a small molecule that targets the SGLT2 receptor. Used for Type 2 diabetes.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":3,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}